Pair page
IGF-1 DES with IGF-1 LR3
Mechanism-tag overlap and published literature for IGF-1 DES and IGF-1 LR3, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
n-terminally-truncated-analog
igf-1-receptor-agonistmodified-protein
long-r3-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying IGF-1 DES and IGF-1 LR3 have published these mechanism-level observations. Not a co-administration recommendation.
IGF-1 LR3 provides sustained systemic IGF-1 activity (20–30 hour active half-life); IGF-1 DES provides concentrated site-specific local action (20–30 minute half-life). Some advanced community protocols use LR3 for systemic anabolic support and DES for site-specific targeting. This is an aggressive stack with additive hypoglycemia risk and cumulative IGF-1-axis stimulation. Not evidence-supported; compounds cancer-risk theoretical concerns.
Quick facts
IGF-1 DES
IGF-1 LR3
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2002 | IGF-1 DES | Philipps AF, Kling PJ, Grille JG, Dvoráková S. Intestinal transport of insulin-like growth factor-I (IGF-I) in the suckling rat. J Pediatr Gastroenterol Nutr. 2002;35(4):539-544. PMID: 12394383. (Colostrum IGF-1 DES context.) PMID 12394383 | preclinical, in vivo |
| 1993 | IGF-1 DES | Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-421. PMID: 8371077. (In vivo anabolic effects of IGF-1 DES vs native IGF-1.) PMID 8371077 | preclinical, in vivo |
| 1991 | IGF-1 DES | Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, Ferraiolo BL. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), des(1-3)IGF-I and IGF-II in rats. J Endocrinol. 1991;131(1):87-93. PMID: 1720984. PMID 1720984 | preclinical, in vivo |
| 1991 | IGF-1 DES | Williams ED, et al. Comparison of des(1-3)IGF-1 and IGF-1 in promoting wound healing. Growth Factors. 1991 context. (Wound-healing preclinical reference.) | preclinical, in vivo |
| 1989 | IGF-1 DES | Sara VR, Carlsson-Skwirut C, Bergman T, Jörnvall H, Roberts PJ, Crawford M, Håkansson LN, Civalero I, Nordberg A. Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. Bioche… PMID 2597159 | mechanism / discovery |
| 1988 | IGF-1 DES | Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC. Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J. 1988;251(1):95-103. PMID: 3401742. (Seminal characterization of IGFBP-… PMID 3401742 | mechanism / discovery |
| 1986 | IGF-1 DES | Sara VR, Carlsson-Skwirut C, Andersson C, Hall E, Sjögren B, Holmgren A, Jörnvall H. Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I. Proc Natl Acad Sci USA. 1986;83(13):4904-4907. PMID: 3459178. (Original… PMID 3459178 | mechanism / discovery |
| 2026 | IGF-1 DES | WADA. 2026 World Anti-Doping Code Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. (IGF-1 and analogs class prohibition.) | regulatory / registry |
| 2005 | IGF-1 DES | U.S. Food and Drug Administration. Increlex (mecasermin) Prescribing Information. Ipsen Biopharmaceuticals. First approved 2005. (Context: FDA-approved recombinant native IGF-1 — different molecule from IGF-1 DES.) | regulatory / registry |
| 2012 | IGF-1 DES | Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-169. PMID: 22473468. (IGF-1 pathway and cancer epidemiology — central class-level safety framing.) PMID 22473468 | research article |
| 2003 | IGF-1 DES | LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195(2):127-137. PMID: 12767520. PMID 12767520 | research article |
| 2001 | IGF-1 DES | Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27(2):195-200. PMID: 11175789. (Foundational muscle-s… PMID 11175789 | research article |
| 2004 | IGF-1 LR3 | Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. (Epidemiologic IGF-1/cancer association.) | systematic review |
| 1999 | IGF-1 LR3 | Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. Horm Res. 1999;51(3):128-134. (Mecasermin European data.) | human study |
| 1993 | IGF-1 LR3 | Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II. Biochem J. 1993;… | mechanism / discovery |
| 1992 | IGF-1 LR3 | Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological poten… | mechanism / discovery |
| 1992 | IGF-1 LR3 | King R, Wells JR, Krieg P, Snoswell M, Brazier J, Bagley CJ, Wallace JC, Ballard FJ, Ross M, Francis GL. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expre… | mechanism / discovery |
| 2026 | IGF-1 LR3 | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (All IGF-1 forms banned under S2.) | regulatory / registry |
| 2026 | IGF-1 LR3 | HHS Secretary Robert F. Kennedy Jr. Public Statement on Peptide Reclassification, February 27, 2026. (Reference for ongoing Category 2 → Category 1 review affecting IGF-1 family.) | regulatory / registry |
| 2025 | IGF-1 LR3 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025–2026. (IGF-1 LR3 Category 2 designation.) | regulatory / registry |
| 2005 | IGF-1 LR3 | Increlex (mecasermin) FDA Approval Documentation. FDA Approval Date: August 31, 2005. Sponsor: Tercica (now Ipsen). Indication: severe primary IGF-1 deficiency in children. (Native rhIGF-1; not IGF-1 LR3.) | regulatory / registry |
| — | IGF-1 LR3 | Thomas A, Solymos E, Schänzer W, Thevis M. Determination of insulin-like growth factor-I and IGF analogues in human serum by liquid chromatography-tandem mass spectrometry. (WADA detection methods for IGF-1 forms including LR3.) | regulatory / registry |
| — | IGF-1 LR3 | Ipsen Pharmaceuticals. Increlex (mecasermin) Prescribing Information. (FDA-approved native rhIGF-1; not IGF-1 LR3.) | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have IGF-1 DES and IGF-1 LR3 been studied together?
Researchers have published mechanistic-level co-administration discussion of IGF-1 DES and IGF-1 LR3. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do IGF-1 DES and IGF-1 LR3 share?
IGF-1 DES and IGF-1 LR3 share these mechanism tags on their Kalios profiles: igf-1-receptor-agonist, modified-protein. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of IGF-1 DES and IGF-1 LR3?
IGF-1 DES: Not approved; research only. IGF-1 LR3: Research only (Category 2 bulk). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on IGF-1 DES and IGF-1 LR3?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the IGF-1 DES profile and the IGF-1 LR3 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026